NCT00237536终止2 期
A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 240
- 试验地点
- 68
- 主要终点
- IPSS
研究概览
简要总结
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 65 Years 至 80 Years（Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Capable of understanding the purpose and risks of the study and sign a statement of informed consent
- •Male 65-80 years of age (or 40-80 with vasectomy). Vasectomized men must have documentation of azoospermia.
- •Presence of LUTS (lower urinary tract symptoms) for at least 3 months
- •Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc
- •Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)
- •IPSS (International Prostate Symptom Score) > 12
- •PSA > 1.0 ng/mL
- •Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential
- •Able to comply with the prescribed treatment protocol and evaluations
排除标准
- •Prior treatment for BPH with alpha blockers and/or herbal supplements for the treatment of BPH in the past 2 weeks (alpha-blockers and/or herbal supplements for the treatment of BPH are not allowed during the study). Prior treatment with 5-alpha reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.
- •Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)
- •Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (For subjects with PSA between 4 - 10 ng/mL, prostate cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA >10 ng/mL are excluded).
- •Active urinary tract infections (UTI)
- •Active cardiac, renal or hepatic disease as evidenced by:
- •Serum creatinine > 1.8 mg/dL
- •ALT or AST > 2.5x the upper limit of normal
- •History of active myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months prior to screening
- •Uncontrolled congestive heart failure
- •Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)
- •Use of systemic steroids for any reason (systemic steroid usage is not allowed during the study). Inhaled and/or topical steroids are allowed.
- •Concurrent participation or participation in an investigational drug study within the past 30 days prior to screening
- •Concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the Investigator, pose an unacceptable risk to the subject
结局指标
主要结局
IPSS
次要结局
- Maximum urinary flow rate (Qmax)
- Post-void residual urine volume (PVR)
- Prostate volume
- Prostate specific antigen (PSA)
研究者
研究点 (68)
Loading locations...
相似试验
终止
3 期
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic HyperplasiaEnlarged ProstateBenign Prostatic HyperplasiaNCT00435448Threshold Pharmaceuticals480
已完成
2 期
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic PainOpioid Induced Bowel DysfunctionNCT01122030Shionogi72
已完成
3 期
Efficacy and Safety of Naldemedine in Treating Opioid-induced ConstipationOpioid-induced ConstipationNCT01993940Shionogi553
已完成
3 期
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced ConstipationOpioid-induced ConstipationNCT01965158Shionogi547
已完成
2 期
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant EpilepsyDrug-resistant EpilepsyFocal-Onset SeizuresNCT03373383UCB Biopharma S.P.R.L.411